Indomethacin for Metabolic Syndrome

This trial aims to examine how the drug Indomethacin affects brain blood flow in individuals with Metabolic Syndrome, a condition characterized by high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels. Researchers seek to determine if these effects differ between males and females. Participants will either have Metabolic Syndrome or serve as healthy controls, receiving both Indomethacin and a placebo at different times. Individuals with at least three symptoms of Metabolic Syndrome, such as high waist size and high blood sugar, may qualify for the trial. As an Early Phase 1 trial, this research focuses on understanding how Indomethacin works in people, offering participants an opportunity to contribute to groundbreaking medical knowledge.

The trial requires that you do not take medications known to influence cardiovascular function, except for contraceptive hormones. This includes medications for blood pressure, diabetes, and cholesterol.

Research has shown that the FDA has approved indomethacin for treating conditions like acute pain and arthritis, indicating its safety for these uses. However, some risks exist. Indomethacin may increase the risk of blood clots, heart attacks, or strokes, particularly with long-term use. It can also cause stomach and digestive issues and affect kidney function. These side effects occur more frequently with extended use, so short-term use in a trial might pose less risk. Always weigh the benefits and risks before deciding to join a study.¹²³⁴⁵

Indomethacin is unique because, unlike other treatments for Metabolic Syndrome that typically focus on managing individual symptoms like high blood pressure, glucose levels, or cholesterol, it targets inflammation, which is thought to play a central role in the syndrome. This anti-inflammatory action represents a potential new approach to addressing the root causes of Metabolic Syndrome. Researchers are excited about indomethacin's potential to provide a more comprehensive treatment option by possibly reducing the overall inflammation associated with the condition, potentially improving multiple symptoms at once.

Research has shown that indomethacin reduces inflammation and pain in conditions like rheumatoid arthritis by lowering swelling and fever. Although primarily used for these conditions, no direct evidence yet supports indomethacin's effectiveness for metabolic syndrome or its symptoms. This trial will explore indomethacin's potential effects on metabolic syndrome, including its influence on blood flow and inflammation. Participants will receive either a placebo followed by indomethacin or indomethacin followed by a placebo. Results from studies on various conditions have been mixed, indicating the need for further research to understand its impact on metabolic syndrome.¹²⁵⁶⁷